In this review, we have described the details of the completed and ongoing clinical trials, which should aid in exploring the appropriate first-line, single-drug or combinatorial, treatment in the previously-untreated patients with advanced NSCLC not harboring EGFR/ALK mutations (Figure 3). Here, ALK is linked to non-small cell lung carcinoma.